Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celltrion
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has disease improvement (moderate or good response) according to Disease Activity Score using 28 joint counts (DAS28) during the last course of treatment in Study CT-P10 1.1.
Patient has completed all of the scheduled visits in the Study CT-P10 1.1 Main Study Period, including the Core Study Period and/or Extension Study Period.
You may not be if
Patient has been withdrawn from Study CT-P10 1.1 for any reason.
Patient has, at the time of providing informed consent, any current medical issues such as serious adverse events (SAEs) or current or previous intolerance issues that mean continuation in this maintenance study could be detrimental to their health, in the opinion of the investigator.
Clareo Health | Long-Term Efficacy and Safety of CT-P10 in Patients With RA
